US approves new anti-leukaemia drugBMJ 2001; 322 doi: http://dx.doi.org/10.1136/bmj.322.7296.1201 (Published 19 May 2001) Cite this as: BMJ 2001;322:1201
- Fred Charatan
A new oral drug to treat chronic myeloid leukaemia has been approved in record time by the US Food and Drug Administration.
At a news conference in Washington, DC, attended by the US secretary of health and human services, Tommy Thompson, and the director of the National Cancer Institute, Dr Richard Klausner, the administration announced its approval of imatinib mesylate (Gleevec).
The new drug, manufactured by Novartis of Basle, Switzerland, was approved after a review of the clinical data lasting only two and a half months. The drug has also proved effective against rare gastrointestinal stromal tumours …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial